#ZTS

@follow-the-money.us

4 days ago

Gilbert Cisneros - Integrity Index View Gilbert Cisneros's political integrity grade, campaign financing, and conflicts of interest.

Rep. Gilbert Cisneros (D-CA) disclosed 60 trades:
Traded: Feb 10 | Disclosed: Mar 9

Bought: $ZTS ($1K-$15K), $FSV ($15K-$50K), $AMD ($1K-$15K), $OXY ($1K-$15K), $ILMN ($1K-$15K), $CTRA ($1K-$15K), $KMI ($1K-$15K), $AMZN ($1K-$15K), $XOM ($50K-$100K), $COP ($1K-$15K), $EQT ($1K-$15K), $STE ($1K-$...

Emil Lazzaroni

@globalcompounders.bsky.social

1 month ago

40. Saving your Good Boy is a Big Business For our fortieth episode, we're talking about a part of our families that often has four legs. [pause] We’re talking about our pets. The trend is undeniable: we've elevated our pets from the backyard to cherished members of the family. We'll spend almost anything to keep them healthy. Today's company is the "Pfizer for your pet." It's the global leader in the medicines, vaccines, and treatments that our veterinarians rely on every single day. We are talking about Zoetis. When you hear the name Zoetis ($ZTS), you might know it as the former animal health division of Pfizer, the largest company in the world dedicated to medicines and vaccines for pets and livestock. It's the dominant leader in a niche corner of the healthcare sector. But the real story behind Zoetis's incredible success isn't just about animal medicine; it's about the powerful and durable "humanization of pets" megatrend. As owners increasingly treat their pets as members of the family, spending on their health and wellness becomes essential and recession-resistant. This has turned Zoetis into a defensive growth powerhouse with a wide competitive moat, serving both the companion animal and livestock markets. But with the stock consistently trading at a premium valuation, is all the good news already priced in? We're checking up on the health of this investment to determine if Zoetis can continue to justify its premium price tag and remain a best-in-breed holding for a long-term portfolio.

📣 New Podcast! "40. Saving your Good Boy is a Big Business" on @Spreaker #animalhealth #cats #defensive #dogs #finance #growth #healthcare #humanization #investing #livestock #moat #pets #pfizer #pharma #portfolio #spinoff #stock #veterinary #zoetis #zts

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

1 month ago

#ZTS #REGN #4db793c9-fb53-4206-b5cb-4661e3784529 #investing #Health #Care

Origin | Interest | Match

Henry-nextinvest

@henry-nextinvest.bsky.social

2 months ago

Overbought watch: These stocks have elevated RSI levels.

The stocks trading at high RSI readings:

1. BA - RSI: 88.7
2. ZTS - RSI: 83.7
3. BALL - RSI: 82.9

Follow for daily market insights like this!

#StockMarket #RSI #TechnicalAnalysis $BA $ZTS $BALL

midgardfinance.com

@midgardfinance.com

2 months ago

My holdings going into 2026 ⬇️ I am currently buying NVR Inc and Evolution AB and trimming Alphabet Inc.

🇺🇸
#ADBE 🖥️🎨
#NVR 🏘️📄
#ZTS 🐾💉
#DECK 👟🔥
#CPRT 🚗🔨
#LULU 🧘‍♀️🎽
#GOOG 🔍🧠

🇸🇪
#EVO.ST 🖥️🃏

🇩🇰
#NOVO-B.CO 💉💊
#COLO-B.CO 🛡️🩹
#DEMANT.CO 👂🔊
#PNDORA.CO 💍🥈

StockTitan

@stocktitan.net

2 months ago

Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering Zoetis (NYSE: ZTS) priced $1.75 billion of 0.25% convertible senior notes due 2029, with a $250 million option for additional notes, and expects the offering to close on December 18, 2025. Net proceeds are estimated at approximately $1,723.2 million (or $1,969.6 million if option exercised).Zoetis intends to use proceeds to fund capped calls (~$163.3 million), purchase ~2.1 million shares for ~$250.3 million now, and repurchase approximately $1.6 billion of common stock (or ~$1.8 billion if option exercised) by Q1 2026.Key terms: 0.25% coupon, maturity June 15, 2029, initial conversion price ~$148.20 (22.5% premium), cap price for capped calls $211.7150 (75% premium).

#ZTS Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering

www.stocktitan.net/news/ZTS/zoetis-announce...

StockTitan

@stocktitan.net

3 months ago

Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering Zoetis Inc. today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144 A of the Securities Act of 1933, as amended. Zoetis also intends to grant the initial...

#ZTS Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

www.stocktitan.net/news/ZTS/zoetis-announce...

StockTitan

@stocktitan.net

3 months ago

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats Zoetis (NYSE:ZTS) announced Health Canada approval of Portela (relfovetmab injection) on December 5, 2025, for alleviating pain associated with osteoarthritis (OA) in cats.Portela is designed to provide three months of OA pain relief from a single injection, targets nerve growth factor (NGF), showed effectiveness in a nine-month field trial in Europe, and was well tolerated including in cats with IRIS stage 1–3 kidney disease. Portela is already approved in the EU and Zoetis anticipates commercial availability in Canada and the EU in 2026.

#ZTS Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

www.stocktitan.net/news/ZTS/zoetis-receives...

StockTitan

@stocktitan.net

3 months ago

Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs Zoetis (NYSE: ZTS) announced on November 26, 2025 that the European Commission granted marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs.Lenivia is described as a long‑acting monoclonal antibody targeting nerve growth factor (NGF) that can reduce OA pain for three months with one injection. A nine‑month field study reported a safety profile with dogs showing increased mobility and decreased pain after one injection. Lenivia will join Librela (bedinvetmab) in Zoetis’ portfolio of OA pain therapies for dogs.

#ZTS Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

www.stocktitan.net/news/ZTS/zoetis-receives...

StockTitan

@stocktitan.net

4 months ago

Zoetis Announces Third Quarter 2025 Results The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. Net income for the third quarter of 2025 was $721 million, or $1.63 per diluted share, an increase of 6% and 9%, respectively, on a reported basis. Adjusted net income 2 for the third quarter of 2025 was $754 million, or $1.70 per diluted...

#ZTS Zoetis Announces Third Quarter 2025 Results

www.stocktitan.net/news/ZTS/zoetis-announce...

StockTitan

@stocktitan.net

4 months ago

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats Zoetis (NYSE:ZTS) received European Commission marketing authorization on October 29, 2025 for Portela (relfovetmab), the first monoclonal antibody therapy approved in the EU with a three-month dosing interval to alleviate osteoarthritis (OA) pain in cats. Portela targets nerve growth factor (NGF) and demonstrated effectiveness and tolerability in a nine-month European field trial, including cats with IRIS stage 1–3 kidney disease. The company expects commercial availability in the EU in 2026. Portela expands Zoetis’ feline OA franchise alongside Solensia, which is approved in >40 countries.

#ZTS Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

www.stocktitan.net/news/ZTS/zoetis-receives...

StockTitan

@stocktitan.net

5 months ago

Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs Zoetis (NYSE: ZTS) announced the EMA CVMP has issued a positive opinion recommending marketing authorization for Lenivia (izenivetmab) to reduce pain from osteoarthritis in dogs.The European Commission is expected to decide in Q4 2025, and Zoetis anticipates commercial availability in the EU in 2026. Lenivia is a monoclonal antibody that binds a different site on nerve growth factor and is designed to reduce OA pain for three months with one injection. A nine-month field study reported increased mobility and decreased pain after one injection.

#ZTS Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

www.stocktitan.net/news/ZTS/zoetis-receives...

🧙🏿‍♂️✨Dabzard the Magnificent ✨ 🧙🏿‍♂️

@djdabzard.bsky.social

5 months ago

a video game character is sitting in the cockpit of a plane with a bunch of buttons ALT: a video game character is sitting in the cockpit of a plane with a bunch of buttons

www.mixcloud.com/Dabzardthedj...

A fun mash of final fantasy 7 and umineko

#squaresoft
#zts
#umineko
#playstation
#visualnovel
#finalfantasy

StockTitan

@stocktitan.net

6 months ago

First 3-Month Arthritis Pain Treatment for Cats: Zoetis' Portela Gains Key EU Panel Support Zoetis receives CVMP positive opinion for Portela, first long-acting anti-NGF mAb for cat osteoarthritis pain. Single injection provides 3 months relief, targeting 40% of cats affected by OA.

#ZTS Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

www.stocktitan.net/news/ZTS/zoetis-receives...

Văzdooh

@vazdooh.bsky.social

6 months ago

#ZTS 155C for Jan. Sign of life. Very rare activity and usually sees low hundreds volume. This will be illiquid, shares recommend.

Sanzhi Kobzhan

@stocks2buy.net

6 months ago

Zoetis Inc. (NYSE:ZTS): A Strong Contender in the Animal Health Industry

#stockMarket #investing #ZTS 📈📉 www.stocks2buynow.com/newsitems/zo...

StockTitan

@stocktitan.net

7 months ago

Zoetis Announces Pricing of $1.85 Billion of Senior Notes Zoetis (NYSE:ZTS) has announced the pricing of a $1.85 billion senior notes offering, comprising of $850 million in 4.150% notes due 2028 and $1 billion in 5.000% notes due 2035. The company plans to use the proceeds primarily to repay existing debt, including $750 million of 4.500% notes and $600 million of 5.400% notes, both due in 2025.The offering is expected to close on August 18, 2025, with major financial institutions including Barclays, BofA Securities, Citigroup, J.P. Morgan, and MUFG Securities Americas serving as joint book-running managers.

#ZTS Zoetis Announces Pricing of $1.85 Billion of Senior Notes

www.stocktitan.net/news/ZTS/zoetis-announce...

StockTitan

@stocktitan.net

7 months ago

#ZTS Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

www.stocktitan.net/news/ZTS/zoetis-announce...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

8 months ago

#ZTS #ODFL #POOL #54a76669-02f0-4fba-89bc-0bfb467e2d46 #investing

Origin | Interest | Match

Vicki Yu

@vickiyu.bsky.social

8 months ago

Doberman Pinscher meets Sea Turtle #MAUISTRONG #CrazyRebels #Bejeweled Collar #LahainaStrong #Hawaii YouTube video by La Vida Hawaii

Took Sakura paddleboarding in her Crazy Rebels #MauiStrong collar that was generously gifted to benefit Maui Humane Society and our #SeaTurtle friend popped up to say hello! #DobermanPinscher #Hawaii #Honu #LahainaStrong #Maui #CHWY #ZTS #Belize #SakuraTheDoberman youtube.com/shorts/WJzcR...

StockTitan

@stocktitan.net

10 months ago

Zoetis Delivers Strong Q1 2025 Results: Pet Products Drive 9% Organic Growth Despite Market Headwinds Latest earnings reveal Zoetis' organic growth success amid foreign exchange impacts. See updated 2025 guidance and performance across US and International markets.

#ZTS Zoetis Announces First Quarter 2025 Results

www.stocktitan.net/news/ZTS/zoetis-announce...

@johniac.bsky.social

10 months ago

SciTech Chronicles. . . . . . . . .May 2nd, 2025 Don't stop thinking about tomorrow. Vol II No. 26 383 links Curated Mission Control RSS Feed Wordpress SubStack Comments Buy Me A Coffee ...

SciTech Chronicles. . . . . . . . .May 2nd, 2025

bit.ly/stc050225

#protoplanets#"moment of inertia" #stratification #SPDX #ZTS #Linux #"6.14 kernel" #respiration #electrons #electrochemistry#"geological history" #"Stac Fada Member" #Rodinia #"gastrointestinal diseases" #metagenomic #metaproteomic

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

10 months ago

www.fool.com/investing/2025/04/26/4-s...

#ABBV #BMY #AMGN #ZTS […]

[Original post on fool.com]

Vicki Yu

@vickiyu.bsky.social

11 months ago

Doberman Pinscher Puppies! Happy #NationalPuppyDay #Shorts #Hawaii #CuteDogs #Dobermann #DobieLove YouTube video by La Vida Hawaii

Happy #NationalPuppyDay! Here are photos of
#FrankieTheRedDoberman #IchiTheDoberman #SakuraTheDoberman and video from the first time we ever met Shadow and Sakura. #doberman #dobermanpinscher #reddoberman #dobermann #reddobie #dogsofX #CHWY #PETS #ZTS
youtube.com/shorts/DKRTI...

@loonietuneseh.bsky.social

1 year ago

US poultry export by country: Mexico, Canada, China. If tariffs in place, maybe chicken farmers will stopping fight chicken vaccination. American will be encouraged to eat vaccinated chicken 😆. #ZTS #tariffs
tinyurl.com/2ax3vf8p

Cees-Jan Kiewiet

@wyrihaxim.us

1 year ago

The recording of it being generated is rather trippy:

#PHP #Threads #Programming #ZTS #ReactPHP #Parallel

StockTitan

@stocktitan.net

1 year ago

Major Breakthrough: Zoetis Secures Emergency Authorization for Vaccine Against Devastating Bird Flu Outbreak Zoetis receives USDA approval for H5N2 avian influenza vaccine as emergency response to crisis affecting 150M+ birds. Builds on company's vaccine expertise.

#ZTS Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus

www.stocktitan.net/news/ZTS/zoetis-receives...

StockTitan

@stocktitan.net

1 year ago

Zoetis Crushes Q4 Earnings: Pet Business Drives Record-Breaking $2.3B Revenue Zoetis delivers impressive Q4 with $2.3B revenue, 11% profit growth, and strong 14% surge in companion animal portfolio, despite livestock segment headwinds.

#ZTS Zoetis Reports Fourth Quarter and Full Year 2024 Results

www.stocktitan.net/news/ZTS/zoetis-reports-...